Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NYSE MKT | Common Stock
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology.
The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is headquartered in Los Angeles, California.
Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | -0.69 Decreased by -72.50% | -0.31 Decreased by -122.58% |
| Mar 21, 24 | -0.55 Decreased by -89.66% | -0.35 Decreased by -57.14% |
| Nov 14, 23 | -0.75 Decreased by -212.50% | -0.31 Decreased by -141.94% |
| Aug 14, 23 | -0.10 Increased by +61.54% | -0.37 Increased by +72.97% |
| May 11, 23 | -0.40 Decreased by -33.33% | -0.32 Decreased by -25.00% |
| Mar 16, 23 | -0.29 Decreased by -26.09% | -0.28 Decreased by -3.57% |
| Nov 9, 22 | -0.24 Decreased by -9.09% | -0.28 Increased by +14.29% |
| Aug 11, 22 | -0.26 Decreased by -4.00% | -0.23 Decreased by -13.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 966.00 K Increased by +21.36% | -25.02 M Decreased by -41.89% | Decreased by -2.59 K% Decreased by -16.92% |
| Dec 31, 23 | 1.53 M Increased by +45.39% | -19.85 M Decreased by -92.67% | Decreased by -1.30 K% Decreased by -32.52% |
| Sep 30, 23 | 1.23 M Decreased by -8.45% | -31.16 M Decreased by -262.13% | Decreased by -2.54 K% Decreased by -295.53% |
| Jun 30, 23 | 980.00 K Decreased by -47.96% | -3.55 M Increased by +61.49% | Decreased by -361.94% Increased by +26.00% |
| Mar 31, 23 | 796.00 K Increased by +N/A% | -17.63 M Decreased by -101.00% | Decreased by -2.22 K% Decreased by N/A% |
| Dec 31, 22 | 1.05 M Increased by +49.06 K% | -10.30 M Decreased by -70.35% | Decreased by -980.11% Increased by +99.65% |
| Sep 30, 22 | 1.34 M Increased by +106.85 K% | -8.61 M Decreased by -58.79% | Decreased by -643.12% Increased by +99.85% |
| Jun 30, 22 | 1.88 M Increased by +61.22% | -9.21 M Decreased by -48.69% | Decreased by -489.11% Increased by +7.77% |